Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unfinished Labeling Business: Pregnancy, In Vitro Data, Containers

Executive Summary

FDA's final labeling rule defers revisions to labeling issues such as the content and format of the Pregnancy subsection, inclusion of in vitro data and the requirements for container labels

You may also be interested in...



Pregnancy Label Due Date Approaching? Risk, Clinical Info Could Be Split

FDA is seeking to move ahead quickly with new regulations for pregnancy labeling following the release of the physician labeling final rule

Pregnancy Label Due Date Approaching? Risk, Clinical Info Could Be Split

FDA is seeking to move ahead quickly with new regulations for pregnancy labeling following the release of the physician labeling final rule

Labeling “Highlights” To Depend On Data In Relation To Clinical Setting

Information to be included in the new Highlights of Prescribing Information section of professional labeling will be determined by the clinical setting in which the drug is used, FDA said

Related Content

UsernamePublicRestriction

Register

PS046871

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel